Communications medicine最新文献

{"title":"A lyophilised formulation of chimpanzee adenovirus vector for long-term stability outside the deep-freeze cold chain.","authors":"Frédéric Mathot, Edwige Lefebvre, Bernard G Francq, Delphine Guillaume, Erwan Bourlès","doi":"10.1038/s43856-025-00740-x","DOIUrl":"10.1038/s43856-025-00740-x","url":null,"abstract":"<p><strong>Background: </strong>The adenovirus-vaccine platform has come to prominence with the COVID-19 vaccination campaigns. The objective of this study was to validate a formulation that was suitable for lyophilisation and long-term storage at 5 (2-8) °C.</p><p><strong>Methods: </strong>Vaccine stability was assessed up to five years at 5 °C using a lyophilised formulation of the chimpanzee-adenovirus vector ChAd155 encoding a respiratory syncytial virus (RSV) antigen. Vaccine potency was assessed by functional infectivity assay. Other assessments of vaccine stability included those for capsid integrity, particle content, and DNA release. Vaccine efficacy and safety were assessed after two years in a murine model of RSV challenge and a rabbit toxicology model, respectively.</p><p><strong>Results: </strong>Here, we show that the potency loss from lyophilisation was 0.12 log₁₀. The potency loss over five years at 5 °C was estimated at 0.21 log₁₀ (95%CI 0.10-0.30). This coincides with a 25% increase in the ratio of non-infectious particles/infectious particles. After two years of storage at 5 °C, (i) the loss of infectivity was 0.17 log₁₀; (ii) the vaccine remained immunogenic and effective at clearing RSV from the lungs in a mouse-challenge model; and (iii) the vaccine was not associated with any adverse safety signal in a rabbit toxicology model.</p><p><strong>Conclusions: </strong>The 5-year stability of the lyophilised adenovirus-vector vaccine is within our acceptable limit ( < 0.3 log₁₀ decrease). Its formulation process is amenable to manufacturing scale-up and should help in providing adenovirus-based vaccines where the cold chain is problematic, such as in low-income countries, and in pre-epidemic stockpiling.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"23"},"PeriodicalIF":5.4,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.","authors":"Timothy Weeden, Tyler Picariello, Brendan Quinn, Sean Spring, Pei-Yi Shen, Qifeng Qiu, Benjamin F Vieira, Lydia Schlaefke, Ryan J Russo, Ya-An Chang, Jin Cui, Monica Yao, Aiyun Wen, Nelson Hsia, Tama Evron, Katy Ovington, Pei-Ni Tsai, Nicholas Yoder, Bo Lan, Reshmii Venkatesan, John Hall, Cody A Desjardins, Mo Qatanani, Scott Hilderbrand, John Najim, Zhenzhi Tang, Matthew K Tanner, Romesh Subramanian, Charles A Thornton, Oxana Ibraghimov-Beskrovnaya, Stefano Zanotti","doi":"10.1038/s43856-025-00733-w","DOIUrl":"10.1038/s43856-025-00733-w","url":null,"abstract":"<p><strong>Background: </strong>We developed the FORCE^TM platform to overcome limitations of oligonucleotide delivery to muscle and enable their applicability to neuromuscular disorders. The platform consists of an antigen-binding fragment, highly specific for the human transferrin receptor 1 (TfR1), conjugated to an oligonucleotide via a cleavable valine-citrulline linker. Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by expanded CUG triplets in the DMPK RNA, which sequester splicing proteins in the nucleus, lead to spliceopathy, and drive disease progression.</p><p><strong>Methods: </strong>Multiple surrogate conjugates were generated to characterize the FORCE platform. DYNE-101 is the conjugate designed to target DMPK and correct spliceopathy for the treatment of DM1. HSA^LR and TfR1^hu/mu;DMSXL^Tg/Tg mice were used as models of myotonic dystrophy, the latter expresses human TfR1 and a human DMPK RNA with >1,000 CUG repeats. Cynomolgus monkeys were used to determine translatability of DYNE-101 pharmacology to higher species.</p><p><strong>Results: </strong>In HSA^LR mice, a surrogate FORCE conjugate achieves durable correction of spliceopathy and improves myotonia to a greater extent than unconjugated ASO. In patient-derived myoblasts, DYNE-101 reduces DMPK RNA and nuclear foci, consequently improving spliceopathy. In TfR1^hu/mu;DMSXL^Tg/Tg mice, DYNE-101 reduces mutant DMPK RNA in muscle, thereby correcting splicing. Reduction of DMPK foci in cardiomyocyte nuclei accompanies these effects. Low monthly dosing of DYNE-101 in TfR1^hu/mu;DMSXL^WT/Tg mice or cynomolgus monkeys leads to a profound reduction of DMPK expression in muscle.</p><p><strong>Conclusions: </strong>These data validate FORCE as a drug delivery platform and support the notion that DM1 may be treatable with low and infrequent dosing of DYNE-101.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"22"},"PeriodicalIF":5.4,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants.","authors":"Odile Launay, Rachna Gupta, Tifany Machabert, Eleine Konate, Alexandra Rousseau, Claire Vigne, Francois Beckers, Louis Devlin, Elisabeth Botelho-Nevers, Marine Cachanado, Christian Chidiac, Dominique Deplanque, Bertrand Dussol, Inès Ben Ghezala, Marie Lachatre, Karine Lacombe, Fabrice Laine, Liem Binh Luong Nguyen, Patricia Pavese, Catherine Schmidt-Mutter, Marie-Pierre Tavolacci, Roman M Chicz, Bogdana Coudsy, Saranya Sridhar, Amel Touati, Eric Tartour, Tabassome Simon","doi":"10.1038/s43856-024-00675-9","DOIUrl":"10.1038/s43856-024-00675-9","url":null,"abstract":"<p><strong>Background: </strong>We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech).</p><p><strong>Methods: </strong>First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay.</p><p><strong>Results: </strong>Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]).</p><p><strong>Conclusions: </strong>The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"21"},"PeriodicalIF":5.4,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.","authors":"Farwa Ali, Jeremy A Syrjanen, Dan J Figdore, Walter K Kremers, Michelle M Mielke, Clifford R Jack, David S Knopman, Prashanthi Vemuri, Jonathan Graff-Radford, B Gwen Windham, Leland R Barnard, Ronald C Petersen, Alicia Algeciras-Schimnich","doi":"10.1038/s43856-024-00713-6","DOIUrl":"10.1038/s43856-024-00713-6","url":null,"abstract":"<p><strong>Background: </strong>Declining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer's disease (Aβ 42/40 ratio, P-Tau181).</p><p><strong>Methods: </strong>In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are associated with worse gait performance. A sample of 2641 Mayo Clinic Study of Aging participants with measurements of plasma biomarkers and gait parameters was analyzed in this cross-sectional study. Linear regression models using plasma biomarkers as predictors of gait parameters and adjusted for age, sex, BMI, Charlson Comorbidity Index, and cognitive diagnosis were evaluated.</p><p><strong>Results: </strong>In this study multiple statistically significant relationships are observed for GFAP, NfL, and P-Tau181 with gait parameters. Each standard deviation increase in GFAP, NfL, and P-Tau181 is associated with a reduction in velocity of 2.100 (95% CI: -3.004, -1.196; p = 5.4 × 10^-6), 4.400 (-5.292, -3.507; p = 9.5 × 10^-22), and 2.617 (-3.414, -1.819; p = 1.5 × 10^-10) cm/sec, respectively. Overall, NfL has the strongest associations with poor gait performance. Models with age interactions show that the strength of associations between the plasma biomarkers and the gait parameters became stronger with increasing age. There are no specific gait parameters that associate with individual plasma biomarkers.</p><p><strong>Conclusion: </strong>Plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are not only markers of cognitive decline but also indicate motor decline in the aging population.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"19"},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing deep learning to detect bronchiolitis obliterans syndrome from chest CT.","authors":"Mateusz Koziński, Doruk Oner, Jakub Gwizdała, Catherine Beigelman-Aubry, Pascal Fua, Angela Koutsokera, Alessio Casutt, Argyro Vraka, Michele De Palma, John-David Aubert, Horst Bischof, Christophe von Garnier, Sahand Jamal Rahi, Martin Urschler, Nahal Mansouri","doi":"10.1038/s43856-025-00732-x","DOIUrl":"10.1038/s43856-025-00732-x","url":null,"abstract":"<p><strong>Background: </strong>Bronchiolitis Obliterans Syndrome (BOS), a fibrotic airway disease that may develop after lung transplantation, conventionally relies on pulmonary function tests (PFTs) for diagnosis due to limitations of CT imaging. Deep neural networks (DNNs) have not previously been used for BOS detection. This study aims to train a DNN to detect BOS in CT scans using an approach tailored for low-data scenarios.</p><p><strong>Methods: </strong>We trained a DNN to detect BOS in CT scans using a co-training method designed to enhance performance in low-data environments. Our method employs an auxiliary task that makes the DNN more sensitive to disease manifestations and less sensitive to the patient's anatomical features. The DNN was tasked with predicting the sequence of two CT scans taken from the same BOS patient at least six months apart. We evaluated this approach on CT scans from 75 post-transplant patients, including 26 with BOS, and used a ROC-AUC metric to assess performance.</p><p><strong>Results: </strong>We show that our DNN method achieves a ROC-AUC of 0.90 (95% CI: 0.840-0.953) in distinguishing BOS from non-BOS in CT scans. Performance correlates with BOS progression, with ROC-AUC values of 0.88 for stage I, 0.91 for stage II, and 0.94 for stage III BOS. Notably, the DNN shows comparable performance on standard- and high-resolution CT scans. It also demonstrates the ability to predict BOS in at-risk patients (FEV1 between 80% and 90% of best FEV1) with a ROC-AUC of 0.87 (95% CI: 0.735-0.974). Using visual interpretation techniques for DNNs, we reveal sensitivity to hyperlucent/hypoattenuated areas indicative of air-trapping or bronchiectasis.</p><p><strong>Conclusions: </strong>Our approach shows potential for improving BOS diagnosis by enabling early detection and management. The ability to detect BOS from standard-resolution scans at any stage of respiration makes this method more accessible than previous approaches. Additionally, our findings highlight that techniques to limit overfitting are crucial for unlocking the potential of DNNs in low-data settings, which could assist clinicians in BOS studies with limited patient data.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"18"},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study.","authors":"Martina Patone, Andrew Jhl Snelling, Holly Tibble, Carol Coupland, Aziz Sheikh, Julia Hippisley-Cox","doi":"10.1038/s43856-024-00720-7","DOIUrl":"10.1038/s43856-024-00720-7","url":null,"abstract":"<p><strong>Background: </strong>Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficient.</p><p><strong>Methods: </strong>Descriptive and multivariable logistic regression analyses were conducted to evaluate uptake, and a self-controlled case series analysis performed to measure the risk of hospital admission (hospitalisation) associated with 49 pre-specified suspected adverse outcomes in the period 2-28 days post-Sotrovimab treatment among eligible patients treated between December 11, 2021 and May 24, 2022.</p><p><strong>Results: </strong>Here we show that among treated and untreated eligible individuals, the mean ages (54.6 years, SD: 16.1 vs 54.1, SD: 18.3) and sex distribution (women: 60.9% vs 58.1%; men: 38.9% vs 41.1%) are similar. There are marked variations in uptake between ethnic groups, which is higher amongst individuals categorised ethnically as Indian (15.0%; 95%CI 13.8, 16.3), Other Asian (13.7%; 95%CI 11.9, 15.8), white (13.4%; 95%CI 13.3, 13.6), and Bangladeshi (11.4%; 95%CI 8.8, 14.6); and lower amongst Black Caribbean individuals (6.4%; 95%CI 5.4, 7.5) and Black Africans (4.7%; 95%CI 4.1, 5.4). We find no increased risk of any of the suspected adverse outcomes in the period 2-28 days post-treatment.</p><p><strong>Conclusions: </strong>We find no safety signals of concern for possible adverse outcomes in the period 2-28 days post treatment with Sotrovimab. However, there is evidence of unequal uptake of Sotrovimab treatment across ethnic groups.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"20"},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing excitation-inhibition imbalance in Alzheimer's disease using multiscale neural model inversion of resting-state functional MRI.","authors":"Guoshi Li, Li-Ming Hsu, Ye Wu, Andrea C Bozoki, Yen-Yu Ian Shih, Pew-Thian Yap","doi":"10.1038/s43856-025-00736-7","DOIUrl":"10.1038/s43856-025-00736-7","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a serious neurodegenerative disorder without a clear understanding of pathophysiology. Recent experimental data have suggested neuronal excitation-inhibition (E-I) imbalance as an essential element of AD pathology, but E-I imbalance has not been systematically mapped out for either local or large-scale neuronal circuits in AD, precluding precise targeting of E-I imbalance in AD treatment.</p><p><strong>Method: </strong>In this work, we apply a Multiscale Neural Model Inversion (MNMI) framework to the resting-state functional MRI data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to identify brain regions with disrupted E-I balance in a large network during AD progression.</p><p><strong>Results: </strong>We observe that both intra-regional and inter-regional E-I balance is progressively disrupted from cognitively normal individuals, to mild cognitive impairment (MCI) and to AD. Also, we find that local inhibitory connections are more significantly impaired than excitatory ones and the strengths of most connections are reduced in MCI and AD, leading to gradual decoupling of neural populations. Moreover, we reveal a core AD network comprised mainly of limbic and cingulate regions. These brain regions exhibit consistent E-I alterations across MCI and AD, and thus may represent important AD biomarkers and therapeutic targets. Lastly, the E-I balance of multiple brain regions in the core AD network is found to be significantly correlated with the cognitive test score.</p><p><strong>Conclusions: </strong>Our study constitutes an important attempt to delineate E-I imbalance in large-scale neuronal circuits during AD progression, which may facilitate the development of new treatment paradigms to restore physiological E-I balance in AD.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"17"},"PeriodicalIF":5.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning empowered sensor fusion boosts infant movement classification.","authors":"Tomas Kulvicius, Dajie Zhang, Luise Poustka, Sven Bölte, Lennart Jahn, Sarah Flügge, Marc Kraft, Markus Zweckstetter, Karin Nielsen-Saines, Florentin Wörgötter, Peter B Marschik","doi":"10.1038/s43856-024-00701-w","DOIUrl":"10.1038/s43856-024-00701-w","url":null,"abstract":"<p><strong>Background: </strong>To assess the integrity of the developing nervous system, the Prechtl general movement assessment (GMA) is recognized for its clinical value in diagnosing neurological impairments in early infancy. GMA has been increasingly augmented through machine learning approaches intending to scale-up its application, circumvent costs in the training of human assessors and further standardize classification of spontaneous motor patterns. Available deep learning tools, all of which are based on single sensor modalities, are however still considerably inferior to that of well-trained human assessors. These approaches are hardly comparable as all models are designed, trained and evaluated on proprietary/silo-data sets.</p><p><strong>Methods: </strong>With this study we propose a sensor fusion approach for assessing fidgety movements (FMs). FMs were recorded from 51 typically developing participants. We compared three different sensor modalities (pressure, inertial, and visual sensors). Various combinations and two sensor fusion approaches (late and early fusion) for infant movement classification were tested to evaluate whether a multi-sensor system outperforms single modality assessments. Convolutional neural network (CNN) architectures were used to classify movement patterns.</p><p><strong>Results: </strong>The performance of the three-sensor fusion (classification accuracy of 94.5%) is significantly higher than that of any single modality evaluated.</p><p><strong>Conclusions: </strong>We show that the sensor fusion approach is a promising avenue for automated classification of infant motor patterns. The development of a robust sensor fusion system may significantly enhance AI-based early recognition of neurofunctions, ultimately facilitating automated early detection of neurodevelopmental conditions.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"16"},"PeriodicalIF":5.4,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Release of apoptosis inhibitor of macrophage (AIM) from pentameric IgM in serum predicts prognosis after hemodialysis initiation.","authors":"Keisuke Yasuda, Akemi Nishijima, Tomoko Inoue, Toshio Takagi, Kazunari Tanabe, Jun Minakuchi, Satoko Arai, Toru Miyazaki","doi":"10.1038/s43856-025-00735-8","DOIUrl":"10.1038/s43856-025-00735-8","url":null,"abstract":"<p><strong>Background: </strong>The optimal timing for initiating dialysis and prognostic markers in chronic kidney disease (CKD) patients are under debate, with mortality and cardiovascular risks varying among patients. This study investigates whether the apoptosis inhibitor of macrophage (AIM), which is mostly bound to pentameric IgM, could serve as an effective indicator.</p><p><strong>Methods: </strong>We prospectively followed 423 patients at dialysis initiation and 563 at various CKD stages. AIM dissociation from IgM and other serum components were measured in their serum samples. In vitro treatment of IgM-AIM complexes with their serum was conducted to assess AIM release from IgM. Survival analysis determined the associations of each variable with mortality and cardiovascular risk, and a cutoff value was calculated and validated using cross-validation.</p><p><strong>Results: </strong>AIM dissociation from IgM increases with CKD progression and correlates with the serum uremic state, as shown by enhanced AIM release from IgM in vitro with sera from patients starting dialysis, but not those at earlier CKD stages. Patients at dialysis initiation with high proportion of serum IgM-free AIM (fAIM%) show elevated uremic toxins and other toxic metabolites, higher mortality, and increased cardiovascular risk compared to those with low fAIM%. This prognostic association is not seen with other CKD biomarkers, such as eGFR, creatinine, or inositol-phosphate. We determined the fAIM% cutoff of 46.27%, which predicts mortality two years post-dialysis initiation.</p><p><strong>Conclusions: </strong>These findings suggest that the serum fAIM% could function as a prognostic marker at dialysis initiation and may have potential as a criterion for determining dialysis timing.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"15"},"PeriodicalIF":5.4,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal study of care needs and behavioural changes in people living with dementia using in-home assessment data.","authors":"Chloe Walsh, Alexander Capstick, Nan Fletcher-Lloyd, Jessica True, Ramin Nilforooshan, Payam Barnaghi","doi":"10.1038/s43856-024-00724-3","DOIUrl":"10.1038/s43856-024-00724-3","url":null,"abstract":"<p><strong>Background: </strong>People living with dementia often experience changes in independence and daily living, affecting their well-being and quality of life. Behavioural changes correlate with cognitive decline, functional impairment, caregiver distress, and care availability.</p><p><strong>Methods: </strong>We use data from a 3-year prospective observational study of 141 people with dementia at home, using the Bristol Activities of Daily Living Scale, Neuropsychiatric Inventory and cognitive assessments, alongside self-reported and healthcare-related data.</p><p><strong>Results: </strong>Here we show, psychiatric behavioural symptoms and difficulties in activities of daily living, fluctuate alongside cognitive decline. 677 activities of daily living and 632 psychiatric behaviour questionnaires are available at intervals of 3 months. Clustering shows three severity-based groups. Mild cognitive decline associates with higher caregiver anxiety, while the most severe group interacts more with community services, but less with hospitals.</p><p><strong>Conclusions: </strong>We characterise behavioural symptoms and difficulties in activities of daily living in dementia, offering clinically relevant insights not commonly considered in current practice. We provide a holistic overview of participants' health during their progression of dementia.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"14"},"PeriodicalIF":5.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}